Amicus Therapeutics, Inc. - יחס שווי כולל של החברה להכנסות FOLD

The EV/Revenue multiple for Amicus Therapeutics (FOLD) reflects current market sentiment, with the 7408.71 mark indicating the current state. Business growth is constrained by the number of patients with rare genetic pathologies and FDA decisions. The orphan drug status of the medications ensures high margins and a stable cash flow. However, geopolitical fragmentation and sanctions complicate international logistics and scientific research.
FOLD (Amicus Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For Amicus Therapeutics (FOLD), this indicator reflects the enterprise value of the business, accounting for net debt, relative to the volume of generated sales. By analyzing the current enterprise value-to-revenue ratio, an investor can assess how effectively the scaling of Pompe disease therapy justifies the company's capitalization, where an increasing multiple signals expectations for the accelerated commercial rollout of the drug.